Clinical study on efficiency of fludarabine-based regimen for the patients with chronic lymphocytic leukemia.
- Author:
Wei-Min WANG
1
;
Hui SUN
;
Xin-Sheng XIE
;
Si-Lin GAN
;
Ping MA
Author Information
1. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Aged;
Aged, 80 and over;
Antineoplastic Combined Chemotherapy Protocols;
therapeutic use;
Cyclophosphamide;
administration & dosage;
Female;
Humans;
Leukemia, Lymphocytic, Chronic, B-Cell;
drug therapy;
Male;
Middle Aged;
Treatment Outcome;
Vidarabine;
administration & dosage;
analogs & derivatives
- From:
Journal of Experimental Hematology
2012;20(1):70-72
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to evaluate the therapeutic effects and adverse reactions of fludarabine-based regimen for patients with chronic lymphocytic leukemia(CLL).18 patients with CLL were treated with F regimen [fludarabine 30 mg/(m(2)·d) intravenously for 3 d, repeatedly every 28 days]. 22 patients were treated with FC regimen [fludarabine 25 mg/(m(2)·d) plus cyclophosphamide 250 mg/(m(2)·d) intravenously for 3 d, repeatedly every 28 days]. The results showed that the rate of complete remission (CR), partial remission (PR) and overall remission (OR) reached 16.7%, 61.1% and 77.8% in the F regimen groups and 59.1%, 40.9% and 100% in the FC regimen groups (P < 0.05, P > 0.05 and P > 0.05), respectively. FC regimen resulted in significantly higher CR rate than that in single-agent fludarabine regimen. The main adverse reactions were myelosuppression and immunosuppression. No significant differences were found between the two regimens. FC regimen did not increase the rate of severe infections. It is concluded that FC regimen can give higher CR rate as compared with F regimen, fludarabine-based regimens is effective and safe first-line regimen for patients with CLL.
